7.05

0.56% -0.04

After Hours: 7.05

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $7.05, with a volume of 88,626. It is down -0.56% in the last 24 hours and down -27.32% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$7.09

Open:

$7.02

24h Volume:

88,626

Relative Volume:

1.06

Market Cap:

$61.55M

Revenue:

$123.24M

Net Income/Loss:

$136.00K

P/E Ratio:

-352.50

EPS:

-0.02

Net Cash Flow:

$-148.99M

1W Performance:

-8.08%

1M Performance:

-27.32%

6M Performance:

-64.03%

1Y Performance:

-63.81%

1-Day Range:

$6.84

$7.33

1-Week Range:

$6.84

$7.79

52-Week Range:

$6.53

$30.60

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

103

Twitter

@SeresTX

Next Earnings Date

2024-10-31

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB Seres Therapeutics Inc	7.05	66.98M	123.24M	136.00K	-148.99M	-0.02
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

May 28, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World

May 28, 2025

May 27, 2025

Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa

May 27, 2025

Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus

May 27, 2025

Seres Therapeutics reports promising biomarker data - Investing.com

May 27, 2025

Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq

May 27, 2025

Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan

May 27, 2025

May 23, 2025

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

May 23, 2025

May 17, 2025

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World

May 17, 2025

May 16, 2025

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts

May 16, 2025

May 12, 2025

Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com

May 12, 2025

May 11, 2025

Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World

May 11, 2025

May 09, 2025

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World

May 09, 2025

May 08, 2025

Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com

May 08, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga

May 08, 2025

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com

May 08, 2025

MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus

May 08, 2025

Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com

May 07, 2025

Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria

May 07, 2025

Seres Therapeutics, Inc. SEC 10-Q Report - TradingView

May 07, 2025

Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks

May 07, 2025

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times

May 07, 2025

Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus

May 07, 2025

Seres Therapeutics Inc Qtrly EPS $3.76 - marketscreener.com

May 07, 2025

May 06, 2025

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail

May 06, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World

May 06, 2025

May 05, 2025

Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

May 05, 2025

May 01, 2025

5 Best Microbiome Companies (May 2025) - Securities.io

May 01, 2025

Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World

May 01, 2025

Apr 29, 2025

Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan

Apr 29, 2025

Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus

Apr 29, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times

Apr 29, 2025

Apr 28, 2025

Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 25, 2025

Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World

Apr 25, 2025

Apr 24, 2025

MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com

Apr 24, 2025